At the beginning of May, the Government of Canada committed $175.6m in funding to Vancouver-based AbCellera Biologics, a biotech company focused on developing antibody-based drugs.
The funding came through the Ministry of Innovation, Science and Economic Development’s Strategic Innovation Fund (SIF). This support for AbCellera’s work comes as part of the government’s Plan to Mobilise Science against Covid-19, which aims to support national projects that will contribute to the global race against Covid-19, as well as improve the country’s resilience against future pandemics.
AbCellera is leveraging its proprietary antibody drug discovery technology to help identify antibodies from blood samples of recovered Covid-19 patients for drug